Qwo
-
Momentum Builds as Malvern-Based Endo Gets Closer to Launch of Its Potential Blockbuster Product
After pushing the launch of its new cellulite treatment, Qwo, to this spring due to the pandemic, Malvern-based Endo International has been building momentum for…
-
Malvern’s Endo Plans to Restructure, Eliminate 560 Positions
Endo International, the Dublin-based pharmaceutical company with its U.S. headquarters in Malvern, has announced plans to restructure the company and eliminate 560 jobs across the…
-
Malvern’s Endo to Acquire Local Company for $658 Million and Bring Its Cellulite-Fighting Drug to Market
Malvern-based Endo Pharmaceuticals has agreed to acquire BioSpecifics Technologies, a 20-year-old company based in Wilmington, for around $658 million, writes Joseph DiStefano for The Philadelphia…
-
New Drug from Malvern’s Endo the First Injectable Treatment for Cellulite Cleared by the FDA
Endo International, the Dublin-based pharmaceutical company with its U.S. headquarters in Malvern, has received marketing approval from the FDA for its injectable drug to treat…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
